SG11202104857PA - Heterocyclic spiro-compounds as am2 receptor inhibitors - Google Patents
Heterocyclic spiro-compounds as am2 receptor inhibitorsInfo
- Publication number
- SG11202104857PA SG11202104857PA SG11202104857PA SG11202104857PA SG11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- receptor inhibitors
- heterocyclic spiro
- spiro
- heterocyclic
- Prior art date
Links
- -1 Heterocyclic spiro-compounds Chemical class 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1818651.0A GB201818651D0 (en) | 2018-11-15 | 2018-11-15 | Compounds |
PCT/GB2019/053236 WO2020099882A1 (fr) | 2018-11-15 | 2019-11-15 | Composés spiro hétérocycliques constituant des inhibiteurs du récepteur de l'am2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104857PA true SG11202104857PA (en) | 2021-06-29 |
Family
ID=64740129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104857PA SG11202104857PA (en) | 2018-11-15 | 2019-11-15 | Heterocyclic spiro-compounds as am2 receptor inhibitors |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220023281A1 (fr) |
EP (1) | EP3880679A1 (fr) |
JP (1) | JP2022507561A (fr) |
KR (1) | KR20210102261A (fr) |
CN (1) | CN113227091A (fr) |
AU (1) | AU2019380715A1 (fr) |
BR (1) | BR112021009381A8 (fr) |
CA (1) | CA3119882A1 (fr) |
GB (1) | GB201818651D0 (fr) |
SG (1) | SG11202104857PA (fr) |
WO (1) | WO2020099882A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
GB201818649D0 (en) * | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004273057C1 (en) * | 2003-09-08 | 2011-06-30 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
JP2008512459A (ja) * | 2004-09-09 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | アリールスピロラクタムcgrp受容体拮抗薬 |
GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
CA2683581A1 (fr) * | 2007-04-11 | 2008-10-23 | Merck & Co., Inc. | Antagonistes du recepteur cgrp comprenant des groupes terminaux amide tertiaire, sulfamide, carbamate et uree |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
WO2009034028A2 (fr) * | 2007-09-07 | 2009-03-19 | Boehringer Ingelheim International Gmbh | Nouveaux composés |
KR20090033583A (ko) * | 2007-10-01 | 2009-04-06 | 주식회사 엘지생명과학 | 글라이신 아릴 아마이드를 포함하는 신규한베타-세크리타제 저해용 화합물 |
AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
WO2010107809A2 (fr) * | 2009-03-17 | 2010-09-23 | Forest Laboratories Holdings Limited | Procédés de préparation de composés inhibiteurs de la dpp-iv |
EP2531502B1 (fr) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phényl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-méthyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phényl]-urée et composés associés, et leur utilisation dans des traitements |
JP2014148491A (ja) * | 2013-02-04 | 2014-08-21 | Kowa Company Ltd | Tlr阻害作用を有するチアゾール誘導体 |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CN107567438B (zh) * | 2015-03-03 | 2021-06-29 | 拜尔哈文制药股份有限公司 | 利鲁唑前药及其用途 |
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
GB201818649D0 (en) * | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
-
2018
- 2018-11-15 GB GBGB1818651.0A patent/GB201818651D0/en not_active Ceased
-
2019
- 2019-11-15 EP EP19809567.1A patent/EP3880679A1/fr active Pending
- 2019-11-15 US US17/293,157 patent/US20220023281A1/en not_active Abandoned
- 2019-11-15 CN CN201980075441.9A patent/CN113227091A/zh active Pending
- 2019-11-15 CA CA3119882A patent/CA3119882A1/fr active Pending
- 2019-11-15 BR BR112021009381A patent/BR112021009381A8/pt unknown
- 2019-11-15 JP JP2021526621A patent/JP2022507561A/ja active Pending
- 2019-11-15 WO PCT/GB2019/053236 patent/WO2020099882A1/fr unknown
- 2019-11-15 KR KR1020217018203A patent/KR20210102261A/ko not_active Application Discontinuation
- 2019-11-15 AU AU2019380715A patent/AU2019380715A1/en not_active Abandoned
- 2019-11-15 SG SG11202104857PA patent/SG11202104857PA/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3880679A1 (fr) | 2021-09-22 |
KR20210102261A (ko) | 2021-08-19 |
AU2019380715A1 (en) | 2021-06-10 |
GB201818651D0 (en) | 2019-01-02 |
CA3119882A1 (fr) | 2020-05-22 |
BR112021009381A2 (pt) | 2021-08-10 |
JP2022507561A (ja) | 2022-01-18 |
WO2020099882A1 (fr) | 2020-05-22 |
CN113227091A (zh) | 2021-08-06 |
BR112021009381A8 (pt) | 2022-03-22 |
US20220023281A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
IL283333A (en) | Heterocyclic compounds | |
IL273428B1 (en) | Heterocyclic compounds as pad inhibitors | |
IL277455A (en) | History of aminopyrimidines as CTPS1 inhibitors | |
IL280821A (en) | Heterocycline compound | |
SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
IL289617A (en) | Heterocyclic compounds | |
IL289595A (en) | Heterocyclic compounds | |
ZA202104402B (en) | Heterocyclic compound | |
SG11202104883TA (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
SG11202104857PA (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
EP3693360C0 (fr) | Composés hétérocycliques | |
SG11202009356RA (en) | Heterocyclic compound | |
EP3347357A4 (fr) | Inhibiteurs des kinases de la famille des kinases tec hétérocycliques | |
IL277340A (en) | The orthocyclic compound | |
GB201808580D0 (en) | Heterocyclic compounds | |
GB201806488D0 (en) | Heterocyclic TADF compounds |